MCID: PPL022
MIFTS: 52

Papilloma

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Papilloma

MalaCards integrated aliases for Papilloma:

Name: Papilloma 11 53 14 71 75
Papillomatosis 11 53 14 71

Classifications:



External Ids:

Disease Ontology 11 DOID:2615
MeSH 43 D010212
NCIt 49 C3713 C7440
SNOMED-CT 68 711329002 82049002
UMLS 71 C0030354 C0205875

Summaries for Papilloma

Disease Ontology: 11 A cell type benign neoplam that is composed of epithelial tissue on papillae of vascularized connective tissue.

MalaCards based summary: Papilloma, also known as papillomatosis, is related to inverted papilloma and squamous cell papilloma. An important gene associated with Papilloma is UBE3A (Ubiquitin Protein Ligase E3A), and among its related pathways/superpathways are Nervous system development and Prolactin Signaling. The drugs Chlorhexidine and Polihexanide have been mentioned in the context of this disorder. Affiliated tissues include cervix, breast and skin, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Decreased human papilloma virus 16 (HPV16) pseudovirus infection

Wikipedia: 75 A papilloma (plural papillomas or papillomata) (papillo- + -oma) is a benign epithelial tumor growing... more...

Related Diseases for Papilloma

Diseases related to Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1253)
# Related Disease Score Top Affiliating Genes
1 inverted papilloma 33.0 TP53 RB1 KRT5 KRT13 CDKN2A
2 squamous cell papilloma 32.9 TP53 CDKN2A
3 intraductal papilloma 32.6 KRT5 KRT14 ERBB2
4 frontal sinus inverted papilloma 32.5 KRT5 KRT13
5 skin papilloma 32.4 TP53 PTEN KRT14 KRT10 CDKN1A
6 inverted transitional papilloma 32.4 KRT5 CDKN2A
7 urinary bladder inverted papilloma 32.4 RB1 CDKN2A
8 anogenital venereal wart 32.3 UBE3A TP53 RB1 CDKN2A
9 subareolar duct papillomatosis 32.3 KRT8 KRT5
10 larynx squamous papilloma 32.2 TP53 CDKN2A
11 human papillomavirus infectious disease 32.1 TP53 PTEN KRT13 FLG ERBB2 CDKN2A
12 lip and oral cavity cancer 32.0 TP53 RB1 KRT13 IVL CDKN2A
13 keratosis, seborrheic 31.7 TP53 KRT5 KRT10 IVL CDKN2A
14 li-fraumeni syndrome 31.7 TP53 RB1 PTEN IGF2 ERBB2 CDKN2A
15 suppressor of tumorigenicity 3 31.6 UBE3A TP53 RB1 CDKN2A CDKN1A
16 cervical cancer 31.5 UBE3A TP53 RB1 PTEN KRT14 ERBB2
17 head and neck cancer 31.2 TP53 PTEN ERBB2 CDKN2A
18 oropharynx cancer 31.2 UBE3A TP53 PTEN KRT5 KRT14 ERBB2
19 transitional cell carcinoma 31.2 TP53 PTEN GSTP1 ERBB2 CDKN1A
20 squamous cell carcinoma, head and neck 31.2 TP53 RB1 PTEN GSTP1 ERBB2 CDKN2A
21 adenocarcinoma 31.1 TP53 RB1 PTEN ERBB2 CDKN2A CDKN1A
22 cervix uteri carcinoma in situ 31.1 TP53 RB1 CDKN2A
23 penile cancer 31.1 UBE3A TP53 CDKN2A
24 squamous cell carcinoma 31.0 TP53 RB1 PTEN KRT14 KRT13 IVL
25 anus cancer 31.0 UBE3A TP53 RB1 ERBB2 CDKN2A
26 verrucous carcinoma 31.0 TP53 KRT5 KRT14 CDKN2A
27 leukoplakia 31.0 KRT8 KRT13 FLG
28 laryngeal squamous cell carcinoma 31.0 TP53 PTEN ERBB2 CDKN2A CDKN1A
29 penile benign neoplasm 30.9 TP53 CDKN2A
30 bladder cancer 30.9 TP53 RB1 PTEN KRT8 GSTP1 ERBB2
31 ductal carcinoma in situ 30.9 TP53 PTEN KRT8 KRT5 KRT14 ERBB2
32 skin benign neoplasm 30.8 TP53 KRT5 KRT14 KRT13
33 cholangiocarcinoma 30.8 TP53 PTEN KRT8 ERBB2 CDKN2A
34 bladder urothelial carcinoma 30.8 TP53 RB1 PTEN ERBB2 CDKN2A CDKN1A
35 vulva cancer 30.8 TP53 PTEN KRT13 ERBB2 CDKN2A
36 vaginal cancer 30.8 UBE3A TP53 PTEN CDKN2A
37 epidermodysplasia verruciformis 1 30.8 UBE3A TP53 RB1 KRT14 IVL CDKN2A
38 skin carcinoma 30.7 TP53 PTEN KRT8 KRT5 KRT14 ERBB2
39 small cell carcinoma 30.7 TP53 PTEN KRT5
40 teratoma 30.7 TP53 PTEN ERBB2 CDKN2A
41 meningioma, familial 30.7 TP53 PTEN IGF2 ERBB2 CDKN2A AMOT
42 esophageal cancer 30.7 TP53 RB1 PTEN KRT14 GSTP1 ERBB2
43 cervical adenocarcinoma 30.7 TP53 KRT8 CDKN2A CDKN1A
44 papillary adenocarcinoma 30.7 TP53 KRT5 ERBB2
45 bowen's disease 30.6 KRT10 IVL
46 cervix carcinoma 30.6 TP53 PTEN ERBB2 CDKN2A
47 cervical squamous cell carcinoma 30.6 TP53 PTEN KRT8 KRT14 KRT10 CDKN2A
48 muir-torre syndrome 30.6 TP53 PTEN KRT5 CDKN2A
49 lymphoepithelioma-like carcinoma 30.6 TP53 KRT5 CDKN2A
50 esophagitis 30.6 TP53 IL4 FLG

Graphical network of the top 20 diseases related to Papilloma:



Diseases related to Papilloma

Symptoms & Phenotypes for Papilloma

GenomeRNAi Phenotypes related to Papilloma according to GeneCards Suite gene sharing:

25 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.94 IFNAR1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-109 9.94 IGF2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.94 IGF2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.94 IFNAR1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-134 9.94 IGF2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.94 IGF2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.94 PTEN
8 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.94 PTEN
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.94 ERBB2 IGF2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.94 ERBB2 PTEN
11 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.94 RB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.94 RB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.94 IFNAR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-181 9.94 RB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.94 IGF2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.94 ERBB2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.94 RB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.94 PTEN
19 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.94 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-34 9.94 IFNAR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-40 9.94 IFNAR1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.94 PTEN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.94 IFNAR1 RB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.94 IFNAR1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.94 RB1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.94 ERBB2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.94 ERBB2 IFNAR1 IGF2 PTEN
28 Increased shRNA abundance (Z-score > 2) GR00366-A-66 9.94 PTEN
29 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.94 IFNAR1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.94 ERBB2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.94 ERBB2 IGF2 PTEN
32 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.94 IFNAR1 PTEN
33 Decreased human papilloma virus 16 (HPV16) pseudovirus infection GR00306-A 9.56 AMOT CDKN2A ERBB2 GSTP1 IFNAR1 IGF2

MGI Mouse Phenotypes related to Papilloma:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.51 AMOT CDKN1A CDKN2A ERBB2 GSTP1 IFNAR1
2 nervous system MP:0003631 10.38 AMOT CDKN1A CDKN2A ERBB2 IFNAR1 IGF2
3 digestive/alimentary MP:0005381 10.31 CDKN1A CDKN2A ERBB2 IFNAR1 IGF2 IL4
4 endocrine/exocrine gland MP:0005379 10.3 CDKN1A CDKN2A ERBB2 IFNAR1 IGF2 IL4
5 neoplasm MP:0002006 10.28 CDKN1A CDKN2A ERBB2 GSTP1 IFNAR1 KRT10
6 cellular MP:0005384 10.23 AMOT CDKN1A CDKN2A ERBB2 IFNAR1 IGF2
7 liver/biliary system MP:0005370 10.21 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT8
8 embryo MP:0005380 10.21 AMOT CDKN1A CDKN2A ERBB2 IGF2 KRT8
9 cardiovascular system MP:0005385 10.21 AMOT CDKN1A CDKN2A ERBB2 IFNAR1 IGF2
10 no phenotypic analysis MP:0003012 10.18 CDKN1A CDKN2A IFNAR1 IGF2 IL4 RB1
11 craniofacial MP:0005382 10.18 CDKN1A ERBB2 IGF2 IL4 KRT10 KRT13
12 immune system MP:0005387 10.18 CDKN1A CDKN2A IFNAR1 IGF2 IL4 KRT10
13 limbs/digits/tail MP:0005371 10.15 CDKN1A ERBB2 IGF2 KRT10 KRT5 PTEN
14 reproductive system MP:0005389 10.13 CDKN1A CDKN2A ERBB2 IFNAR1 IGF2 IL4
15 respiratory system MP:0005388 10.07 CDKN1A CDKN2A ERBB2 IFNAR1 IGF2 IL4
16 skeleton MP:0005390 9.96 CDKN1A CDKN2A ERBB2 IFNAR1 IGF2 IL4
17 hematopoietic system MP:0005397 9.93 CDKN1A CDKN2A ERBB2 IFNAR1 IGF2 IL4
18 mortality/aging MP:0010768 9.86 AMOT CDKN1A CDKN2A ERBB2 IFNAR1 IGF2
19 integument MP:0010771 9.47 CDKN1A CDKN2A ERBB2 GSTP1 IFNAR1 IGF2

Drugs & Therapeutics for Papilloma

Drugs for Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
2
Polihexanide Approved, Investigational Phase 4 28757-47-3 20977
3
Cidofovir Approved Phase 4 113852-37-2 60613
4
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6 Biguanides Phase 4
7 Hypoglycemic Agents Phase 4
8 Disinfectants Phase 4
9 Anti-Infective Agents, Local Phase 4
10 Chlorhexidine gluconate Phase 4
11 Immunoglobulins Phase 4
12 Antibodies Phase 4
13 Epinephryl borate Phase 4
14 Bronchodilator Agents Phase 4
15 Adrenergic beta-Agonists Phase 4
16 Adrenergic alpha-Agonists Phase 4
17 Adrenergic Agonists Phase 4
18 Anti-Asthmatic Agents Phase 4
19 Sodium Channel Blockers Phase 4
20 Vasoconstrictor Agents Phase 4
21 Anesthetics, Local Phase 4
22 Respiratory System Agents Phase 4
23 Mydriatics Phase 4
24 Sympathomimetics Phase 4
25 Diuretics, Potassium Sparing Phase 4
26 Vaccines Phase 3
27
Erlotinib Approved, Investigational Phase 1, Phase 2 183319-69-9, 183321-74-6 176870
28
Avelumab Approved, Investigational Phase 2 1537032-82-8
29
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
30
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
31
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
32
Masoprocol Approved, Investigational Phase 1, Phase 2 500-38-9, 27686-84-6 71398
33
Cianidanol Approved, Withdrawn Phase 2 154-23-4 9064
34
Lenograstim Approved, Investigational Phase 2 135968-09-1
35
Nivolumab Approved Phase 2 946414-94-4
36
Hydroxyurea Approved Phase 2 127-07-1 3657
37
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
38
Durvalumab Approved, Investigational Phase 2 1428935-60-7
39
Nelfinavir Approved Phase 2 159989-64-7 64143
40
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
41
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
42
Cetuximab Approved Phase 2 205923-56-4
43
Fluorouracil Approved Phase 2 51-21-8 3385
44
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
45
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
46
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
47
Panitumumab Approved, Investigational Phase 2 339177-26-3
48
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
49
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 68-26-8 5280382 445354
50
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960

Interventional clinical trials:

(show top 50) (show all 262)
# Name Status NCT ID Phase Drugs
1 Immunogenicity, Compliance, Knowledge and Attitudes in Postpartum Women During a Two Dose 9-valent HPV Vaccination Series Unknown status NCT04311528 Phase 4
2 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Completed NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
3 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
4 Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students Completed NCT04459221 Phase 4 Gardasil 9, 9-Valent Intramuscular Suspension
5 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
6 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) Recruiting NCT03350698 Phase 4
7 Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections. Recruiting NCT04232917 Phase 4 2LPAPI®;Placebo
8 GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose Recruiting NCT03943875 Phase 4
9 Immunogenicity and Safety of Concomitant Inoculation of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia Coli) and Measles Mumps and Rubella Combined Vaccine, Live Active, not recruiting NCT05279248 Phase 4
10 Study on the Immunogenicity and Safety of Co-immunization With Recombinant Human Papillomavirus 16/18 Bivalent Vaccine and Hepatitis E Vaccine Active, not recruiting NCT05415345 Phase 4
11 A Pilot Study of the Immunogenicity of a Two-dose Protocol for 9-valent Human Papilloma Virus Vaccination in Postpartum Girls and Women (15-45 Years Old) Previously Unvaccinated Against HPV Active, not recruiting NCT04274153 Phase 4
12 Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study) Active, not recruiting NCT03391921 Phase 4
13 Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures Not yet recruiting NCT05294640 Phase 4 0.9% Bacteriostatic Local Anesthetic Injection;1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection
14 Immunogenicity of 9-valent HPV Vaccine in Immunocompromised Children and Adolescents Not yet recruiting NCT05439083 Phase 4
15 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
16 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Withdrawn NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
17 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
18 A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years Unknown status NCT02733068 Phase 3
19 Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place Unknown status NCT03296397 Phase 3
20 Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.). Unknown status NCT02382900 Phase 3
21 Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
22 Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
23 Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study Completed NCT00090220 Phase 3
24 Quadrivalent and Bivalent Human Papilloma Virus Vaccines in the Treatment of Common Recalcitrant Warts Completed NCT05383625 Phase 3 Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine;Bivalent Human Papilloma Virus Vaccine;Saline
25 A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men Completed NCT01862874 Phase 3
26 A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys Completed NCT02576054 Phase 3
27 A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men Completed NCT02114385 Phase 3
28 An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil®9) in Solid Organ Transplant Recipients and HIV-infected Patients Completed NCT03525210 Phase 3
29 Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis Completed NCT01375868 Phase 3
30 The Effects of Probiotic Against Reducing Abundance of Human Papilloma Virus (HPV) in Women Recruiting NCT05316064 Phase 2, Phase 3
31 ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study Active, not recruiting NCT02135419 Phase 3 imiquimod;fluorouracil
32 A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls Active, not recruiting NCT02834637 Phase 3 bivalent HPV vaccine;nonavalent HPV vaccine
33 Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions Not yet recruiting NCT03289260 Phase 3 Imiquimod 5% cream;Placebo cream
34 A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV Not yet recruiting NCT05495906 Phase 3
35 Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis Withdrawn NCT01058317 Phase 2, Phase 3 Propranolol
36 Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx Unknown status NCT00002454 Phase 2
37 Phase I/II and Multicenter Trial of HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of Human Papilloma Virus (HPV) Infection Unknown status NCT03351855 Phase 1, Phase 2
38 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Unknown status NCT03302858 Phase 2
39 Single Center, Placebo Controlled, Double-Blind Study to the Treatment of HPV Infected Cervix With AV2 Antiviral Spray and Assessment of Viral Load Unknown status NCT01654822 Phase 2 topical application cervical spray;topical spray on the cervix
40 Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02555800 Phase 2 Bevacizumab;Cidofovir
41 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
42 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
43 A Phase II Study of Avelumab in Subjects With Recurrent Respiratory Papillomatosis Completed NCT02859454 Phase 2 Avelumab
44 A Phase II Study of M7824 in Subjects With Recurrent Respiratory Papillomatosis Completed NCT03707587 Phase 2 M7824
45 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
46 A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women Completed NCT00520598 Phase 2 Comparator: V505 formulation 2
47 A Multicenter, Open Label Phase I/II Study to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101/ISA101b) Immunotherapy in Combination With Standard of Care Therapy (Carboplatin and Paclitaxel With or Without Bevacizumab) in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer Who Have no Curative Treatment Options Completed NCT02128126 Phase 1, Phase 2 ISA101/ISA101b
48 Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery Completed NCT02827838 Phase 2
49 Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy Completed NCT00005941 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
50 A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins Completed NCT00002916 Phase 2

Search NIH Clinical Center for Papilloma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


podophyllin
PODOPHYLLIN PWDR

Genetic Tests for Papilloma

Anatomical Context for Papilloma

Organs/tissues related to Papilloma:

MalaCards : Cervix, Breast, Skin, Endothelial, Lung, Brain, Kidney

Publications for Papilloma

Articles related to Papilloma:

(show top 50) (show all 18649)
# Title Authors PMID Year
1
Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. 53 62
20395210 2010
2
No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. 53 62
19621447 2009
3
Expression of p14ARF, p16INK4a and p53 in relation to HPV in (pre-)malignant squamous skin tumours. 53 62
18681909 2009
4
Colonic adenoma with squamous metaplasia. 53 62
18701516 2009
5
Human papilloma virus type16 E6 deregulates CHK1 and sensitizes human fibroblasts to environmental carcinogens independently of its effect on p53. 53 62
19411857 2009
6
FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. 53 62
19287463 2009
7
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. 53 62
19060248 2009
8
Primary adenosquamous carcinoma of the colon: report of five cases. 53 62
19562453 2009
9
Identification of human papillomavirus in esophageal squamous papillomas. 53 62
19084918 2008
10
Staining characteristics of p16INK4a: is there a correlation with lesion grade or high-risk human papilloma virus positivity? 53 62
18958930 2008
11
Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions. 53 62
18300235 2008
12
Re: Paula M.J. Moonen, Judith M.J.E. Bakkers, Lambertus A.L.M. Kiemenay et al. Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 2007;52:464-9. 53 62
17920185 2008
13
Expression of p16 in conjunctival intraepithelial neoplasia does not correlate with HPV-infection. 53 62
19516893 2008
14
On the mechanism of phenotypic conversion of human cervical adenocarcinoma HeLa cells surviving infection by influenza B virus: potential implications for biological management of adenocarcinomas. 53 62
18291599 2008
15
[Efficacy of local use of recombinant interferon alpha-2 preparations in combined treatment of recurrent respiratory papillomatosis]. 53 62
18833124 2008
16
Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. 53 62
18180113 2008
17
Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein. 53 62
17977825 2007
18
Overexpression of p27kip1 in urinary bladder urothelial carcinoma. 53 62
18036045 2007
19
Hydrogen peroxide induces apoptosis in HeLa cells through mitochondrial pathway. 53 62
17855174 2007
20
Carotenoids suppress proliferating cell nuclear antigen and cyclin D1 expression in oral carcinogenic models. 53 62
17369034 2007
21
Estimation of prognoses for cervical intraepithelial neoplasia 2 by p16INK4a immunoexpression and high-risk HPV in situ hybridization signal types. 53 62
17638654 2007
22
Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. 53 62
17116360 2007
23
Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. 53 62
17551924 2007
24
The expression of p16 (INK4a) and Ki-67 in relation to high-risk human papilloma viral load and residual disease after conization with positive margins. 53 62
17367326 2007
25
Possible prognostic significance of p53 and Ki 67 in inverted sinonasal papilloma. 53 62
17847937 2007
26
A novel mutation of PTEN gene in a patient with Cowden syndrome with excessive papillomatosis of the lips, discrete cutaneous lesions, and gastrointestinal polyposis. 53 62
17489063 2007
27
Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. 53 62
17294450 2007
28
[Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53]. 53 62
17685229 2007
29
Ubiquitin-dependent proteolysis of trihydrophobin 1 (TH1) by the human papilloma virus E6-associated protein (E6-AP). 53 62
17131388 2007
30
Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia. 53 62
17414102 2007
31
[Association of p16, p53, Ki-67 expressions with high-risk human papilloma virus infection in cervical intraepithelial neoplasia]. 53 62
17545048 2007
32
Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. 53 62
17295644 2007
33
The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. 53 62
16698948 2007
34
Increased expression of fascin associated with malignant transformation of sinonasal inverted papilloma. 53 62
17376306 2007
35
Protein expression of the tumor suppressors p16INK4A and p53 and disease progression in recurrent respiratory papillomatosis. 53 62
17277618 2007
36
The history of the angiogenic switch concept. 53 62
16990761 2007
37
[Risk factors and clinical characteristic patients with vulvar cancer]. 53 62
17373116 2006
38
Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. 53 62
16965327 2006
39
Relationship between cyclin G1 and human papilloma virus infection in cervical intraepithelial neoplasia and cervical carcinoma. 53 62
16845792 2006
40
Papilloma protein E6 abrogates shear stress-dependent survival in human endothelial cells: evidence for specialized functions of paxillin. 53 62
16624261 2006
41
Relationship between p21 and p53 expression, human papilloma virus infection and malignant transformation in sinonasal-inverted papilloma. 53 62
16703747 2006
42
Mutation of p53 in skin papilloma and tubular breast adenoma of albino mice. 53 62
16624193 2006
43
E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway. 53 62
16205640 2006
44
Comparative study of the expression of cellular cycle proteins in cervical intraepithelial lesions. 53 62
16979303 2006
45
Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. 53 62
17310826 2006
46
Human papilloma virus and p53 expression in bladder cancer in Egypt: relationship to schistosomiasis and clinicopathologic factors. 53 62
16998598 2006
47
Cell cycle regulatory protein expression profiles by adenovirus p53 infection in human papilloma virus-associated cervical cancer cells. 53 62
19771278 2006
48
The expression of P53 protein and infection of human papilloma virus in conjunctival and eyelid neoplasms. 53 62
16142387 2005
49
Markers of malignant transformation of sinonasal inverted papilloma. 53 62
16005600 2005
50
Immunohistochemical evaluation of intermediate filament proteins in squamous papilloma and oral verrucous carcinoma. 53 62
16120114 2005

Variations for Papilloma

Expression for Papilloma

Search GEO for disease gene expression data for Papilloma.

Pathways for Papilloma

Pathways related to Papilloma according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.67 CDKN1A ERBB2 FLG IVL KRT10 KRT13
2
Show member pathways
13.43 CDKN1A CDKN2A ERBB2 IGF2 IL4 PTEN
3
Show member pathways
12.91 TP53 PTEN IL4 IGF2 IFNAR1 CDKN1A
4
Show member pathways
12.61 CDKN1A CDKN2A ERBB2 PTEN RB1 TP53
5
Show member pathways
12.58 TP53 RB1 IL4 IGF2 IFNAR1
6 12.58 TP53 PTEN IGF2 CDKN2A CDKN1A AMOT
7 12.49 KRT8 KRT5 KRT13 KRT10 AMOT
8 12.45 TP53 RB1 GSTP1 CDKN2A CDKN1A
9
Show member pathways
12.4 TP53 RB1 PTEN ERBB2 CDKN1A
10
Show member pathways
12.4 KRT8 KRT5 KRT14 KRT13 KRT10 IVL
11
Show member pathways
12.21 TP53 RB1 CDKN2A CDKN1A
12
Show member pathways
12.16 TP53 RB1 PTEN CDKN1A
13
Show member pathways
12.16 CDKN1A ERBB2 PTEN RB1 TP53
14
Show member pathways
12.15 TP53 PTEN IL4 IGF2 CDKN1A
15
Show member pathways
12.07 TP53 RB1 CDKN2A CDKN1A
16 12.01 TP53 RB1 PTEN CDKN1A
17 11.87 TP53 PTEN ERBB2 CDKN1A
18 11.83 TP53 RB1 PTEN CDKN1A
19
Show member pathways
11.81 TP53 PTEN IL4 IFNAR1 CDKN2A CDKN1A
20 11.79 TP53 RB1 CDKN1A
21 11.79 TP53 RB1 PTEN CDKN2A CDKN1A
22 11.71 UBE3A PTEN IGF2
23 11.66 RB1 CDKN2A CDKN1A
24 11.63 TP53 PTEN ERBB2
25 11.6 TP53 PTEN IL4 CDKN2A
26 11.57 RB1 CDKN2A CDKN1A
27 11.56 CDKN1A CDKN2A RB1 TP53 UBE3A
28 11.54 CDKN1A IL4 KRT14 KRT5 TP53
29 11.48 KRT5 KRT14 CDKN2A
30 11.48 UBE3A TP53 RB1 CDKN2A
31 11.37 PTEN RB1 TP53
32 11.29 TP53 RB1 CDKN2A
33 11.05 TP53 RB1 CDKN2A
34
Show member pathways
11 TP53 CDKN2A CDKN1A
35 10.96 TP53 RB1 ERBB2 CDKN2A CDKN1A
36 10.96 TP53 RB1 PTEN ERBB2 CDKN2A CDKN1A
37
Show member pathways
10.57 TP53 CDKN1A
38 10.57 TP53 RB1
39 10.43 TP53 CDKN1A

GO Terms for Papilloma

Cellular components related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10.49 AMOT CDKN1A CDKN2A ERBB2 FLG GSTP1
2 intermediate filament GO:0005882 9.81 KRT10 KRT13 KRT14 KRT5 KRT8
3 cornified envelope GO:0001533 9.56 KRT14 KRT10 IVL FLG
4 keratin filament GO:0045095 9.32 KRT8 KRT5 KRT14 KRT13 KRT10

Biological processes related to Papilloma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell cycle GO:0051726 10.11 TP53 RB1 PTEN CDKN2A CDKN1A
2 negative regulation of cell growth GO:0030308 10.03 TP53 RB1 CDKN2A CDKN1A
3 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.97 RB1 PTEN CDKN1A
4 Ras protein signal transduction GO:0007265 9.86 TP53 RB1 CDKN2A CDKN1A
5 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.85 CDKN1A CDKN2A PTEN
6 negative regulation of acute inflammatory response GO:0002674 9.81 IL4 GSTP1
7 peptide cross-linking GO:0018149 9.8 KRT10 IVL FLG
8 intermediate filament organization GO:0045109 9.76 KRT8 KRT5 KRT14 KRT13
9 negative regulation of immature T cell proliferation in thymus GO:0033088 9.65 ERBB2 CDKN2A
10 signal transduction by p53 class mediator GO:0072331 9.58 TP53 CDKN1A
11 replicative senescence GO:0090399 9.43 TP53 CDKN2A CDKN1A
12 keratinocyte differentiation GO:0030216 9.23 KRT14 KRT10 IVL FLG

Molecular functions related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 9.35 TP53 RB1 CDKN2A
2 structural constituent of skin epidermis GO:0030280 9.23 KRT8 KRT5 KRT10 FLG

Sources for Papilloma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....